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IMPORTANCE A proof-of-principle study suggested that intravenous zoledronicacid may 
reduce knee pain and the size of bone marrow lesions in people with knee osteoarthritis, but 
data from large trials are lacking. 
OBJECTIVE To determine the effects of intravenous zoledronic acid on knee cartilage volume 
loss in patients with symptomatic knee osteoarthritis and bone marrow lesions. 
DESIGN, SETTING, AND PARTICIPANTS A 24-month multicenter, double-blind 
placebo-controlled randomized clinical trial conducted at 4 sites in Australia (1 research 
center and 3 hospitals). Adults aged 50 years or older with symptomatic knee osteoarthritis 
and subchondral bone marrow lesions detected by magnetic resonance imaging (MRI) were 
enrolled from November 2013 through September 2015. The final date of follow-up was 
October 9, 2017. 
INTERVENTIONS Intravenous infusion with either 5 mg of zoledronic acid in a 100-ml saline 
solution (n = 113) or a placebo saline solution (n = 110) at baseline and 12 months. 
MAIN OUTCOMES AND MEASURES The primary outcome was absolute change in tibiofemoral 
cartilage volume assessed using MRI over 24 months (the minimum clinically important 
difference [MCID] has not been established). Three prespecified secondary outcomes were 
change in knee pain assessed by a visual analog scale (0 [no pain] to 100 [unbearable pain]; 
MCID, 15) and the Western Ontario and McMaster Universities Osteoarthritis Index (O [no pain] 
to 500 [unbearable pain]; MCID, 75) over 3, 6, 12, 18, and 24 months and change in bone 
marrow lesion size over 6 and 24 months (the MCID has not been established). 
RESULTS Of 223 participants enrolled (mean age, 62.0 years [SD, 8.0 years]; 52% were 
female), 190 (85%) completed the trial. Change in tibiofemoral cartilage volume was not 
significantly different between the zoledronic acid group and the placebo group over 24 
months (-878 mm3 vs - 919 mm3; between-group difference, 41 mm3 [95% Cl, - 79 to 
161 mm3]; P = .SO). No significant between-group differences were found for any of the 
prespecified secondary outcomes, including changes in knee pain assessed by a visual analog 
scale (- 11.5 in the zoledronic acid group vs -16.8 in the placebo group; between-group 
difference, 5.2 [95% Cl, - 2.3 to 12.8); P = .17), changes in knee pain assessed by the Western 
Ontario and McMaster Universities Osteoarthritis Index (- 37.5 vs - 58.0, respectively; 
between-group difference, 20.5 [95% Cl, - 11.2 to 52.2); P = .21), and changes in bone marrow 
lesion size (- 33 mm2vs -6 mm2; between-group difference, - 27 mm2 [95% Cl, - 127 to 73 
mm2]; P = .60) over 24 months. Adverse events were more common with zoledronic acid 
than with placebo (96% vs 83%, respectively) and consisted mainly of acute reactions 
(defined as symptoms within 3 days of administration of infusion; 87% vs 56%). 
CONCLUSIONS AND RELEVANCE Among patients with symptomatic knee osteoarthritis and 
bone marrow lesions, yearly zoledronic acid infusions, compared with placebo, did not 
significantly reduce cartilage volume loss over 24 months. These findings do not support the 
use of zoledronic acid in the treatment of knee osteoarthritis. 
TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12613000039785 
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O steoarthritis is the most common form of arthritis,affecting 250 million people worldwide.1 Kneeosteoarthritis is characterized by knee pain and
structural changes, leading to disability, impaired quality of
life, and economic burden.2-4 Alleviating pain and preventing
structural progression are 2 major treatment goals for
osteoarthritis.5 However, pain control remains poor in more
than half of patients,6 and no approved disease-modifying
therapies have been identified that prevent structural pro-
gression of knee osteoarthritis.
Subchondral bone resorption and turnover contribute
to the pathogenesis of osteoarthritis. In animals, treatment
with bisphosphonates reduced cartilage deterioration by
inhibiting subchondral bone resorption in a dose-response
manner.7-9 However, the results from randomized clinical
trials (RCTs) in humans have been mixed. A meta-analysis10
of 7 RCTs concluded that bisphosphonates were ineffective
for knee symptoms and radiographic progression in patients
with knee osteoarthritis, but the authors stated that bisphos-
phonates may be beneficial in patients with high rates of
bone turnover. Subchondral bone marrow lesions visible on
magnetic resonance imaging (MRI) identify regions of high
bone turnover that may be associated with greater response
to bisphosphonates.11
In a pilot study, zoledronic acid (an intravenous bisphos-
phonate) reduced knee pain and bone marrow lesion size in
patients with knee osteoarthritis and subchondral bone mar-
row lesions after 6 months.12 Given that bone marrow lesions
were associated with faster cartilage volume loss13 (an impor-
tant measure of knee structural progression), the current mul-
ticenter RCT assessed whether zoledronic acid reduced knee
pain, bone marrow lesion size, and cartilage volume loss in pa-
tients with knee osteoarthritis and bone marrow lesions at
24-month follow-up. This study assessed the effects of 2 an-
nual infusions with 5 mg of zoledronic acid on knee cartilage
volume loss in participants with symptomatic knee osteoar-
thritis and bone marrow lesions over 24 months.
Methods
Trial Design
The Zoledronic Acid for Osteoarthritis Knee Pain (ZAP2) study
was a multicenter, double-blind placebo-controlled RCT con-
ducted in Australia. Participants were recruited via the Osteo-
arthritis Clinical Trial Network at 4 sites (in Adelaide, Hobart,
Melbourne, and Sydney) in collaboration with general practi-
tioners, rheumatologists, and orthopedic surgeons, and with
advertising through local and social media. Details of the trial
design have been published14 and are provided in the study
protocol (eAppendix in Supplement 1).
The trial was registered on the Australian New Zealand
Clinical Trials Registry prior to recruitment. Ethics approval
was obtained from the Tasmania Health and Medical human
research ethics committee (H0012941), the Alfred Hospital
ethics committee (03/13), the Monash University human
research ethics committee (CF14/1064-2014000452), the
Northern Sydney Coast human research ethics committee
(HREC/13/HAWKE/80), and the Queen Elizabeth Hospital
human research ethics committee (TQEH/LMH/MH and
HREC/13/TQEHLMH/134). All participants provided written
informed consent.
Participants
Inclusion and exclusion criteria are detailed in the published
protocol14 and are identical with that in the pilot study.12 Par-
ticipants were eligible if aged 50 years or older with knee pain
(defined as a pain score ≥40 mm on a 100-mm visual analog
scale [VAS]) on most days during the last month, met the Ameri-
can College of Rheumatology criteria for symptomatic knee
osteoarthritis15 as assessed by a rheumatologist, and had a sub-
chondral bone marrow lesion present on MRI.
Exclusion criteria included prior use of bisphosphonates (ex-
cept according to a washout schedule), abnormal blood test re-
sults (serum calcium level >2.75 mmol/L or <2.00 mmol/L, cre-
atinine clearance <35 mL/min, or serum 25-hydroxyvitamin D
<40 nmol/L), grade 3 joint space narrowing (JSN) on radio-
graph using the Osteoarthritis Research Society International
atlas (grade 0 [normal] to 3 [severe]),16 other forms of arthritis
(eg, rheumatoid arthritis), poor dental health, arthroscopy or
open surgery in the study knee during the last 12 months,
planned knee replacement, cancer, or contraindication to MRI.14
When a participant had 2 eligible knees, the knee with the
worst pain and mild JSN was selected as the study knee.
Randomization and Blinding
Stratified randomization was conducted by each study site
based on computer-generated block randomization with a
block size of 10. This procedure was performed by a staff mem-
ber without other study involvement. Allocation conceal-
ment was ensured using visually identical infusions (ie, clear
and colorless) for each group. Research nurses administered
the treatments and investigators assessed the outcomes while
blinded to treatment allocation.
Interventions
Participants were randomly assigned in a 1:1 ratio to receive a
single 15-minute intravenous infusion of either zoledronic acid
(5 mg in a 100-mL saline solution) or identical placebo (100-mL
saline solution) at baseline and at 12 months and were fol-
lowed up until 24 months.
Key Points
Question Is zoledronic acid effective for reducing knee cartilage
loss in patients with symptomatic knee osteoarthritis and bone
marrow lesions?
Findings In this randomized clinical trial that included 223 adults,
the mean change in tibiofemoral cartilage volume over 24 months
was −878 mm3 in the zoledronic acid group and −919 mm3 in the
placebo group, a difference that was not statistically significant.
Meaning The findings do not support the use of zoledronic acid
for slowing cartilage volume loss in patients with knee
osteoarthritis.
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Figure 1. Examples of the Measurement of Femoral (A. B. C. and D) and Tibial (E and F) Cartilage Volume and Bone Marrow Lesion Size (G and H) 
A, Delineation of an initial estimate of the bone cartilage interfaces. B. 
Automatic deformation of the bone cartilage contour estimates by the 2- or 
3-dimenslonal active contour process. c. Delineation of an initial estimate of the 
cartilage soft tissue interfaces. D. Automatic defonnatlon of the cartilage soft 
contour estimates by the 2- or 3-dimenslonal active contour process. E. The 
manual drawing process of disarticulation contours around the tibial cartilage 
boundaries. This was done on a section-by-section basis, and then a 
3-dimenslonal rendering (F) was conducted to calculate the volume of the tibial 
Outcomes 
The primary outcome was absolute change in tibiofemoral car-
tilage volume assessed using MRI over 24 months. The mini-
mal clinically important difference for cartilage volume loss 
has not been established. 
The secondary outcomes were change in total bone mar-
row lesion size after 6 and 24 months and change in knee pain 
after 3, 6, 12, 18, and 24 months (assessed using a VAS pain score 
[0-100 mm] and the Western Ontario and McMaster Univer-
sities Osteoarthritis Index17 [WOMAC] pain score [0-500 mm]). 
A proxy for a clinically important difference of140 mm2 was 
defined for change in bone marrow lesion size. This cutoff 
was used in the pilot study12 given that a change in bone mar-
row lesion size of140 mm2 was associated with a I-point change 
in pain score (as assessed by a WOMAC pain score of 0-45). 18 
The minimal clinically important difference was 15 for the VAS 
pain score and 75 for the WOMAC pain score.19 
Assessments Using MRI 
Magnetic resonance imaging scans of the study knee were per-
formed at screening and at 6 and 24 months usingl.5-Tor 3-T 
whole-body MRI units with a commercial transmit-receive knee 
coil. For each participant, the same scanner at each site was 
used throughout the study. The sequences and parameters of 
the MRI units used at each site were described.14 Participants 
who withdrew from the study after 9 months of follow-up were 
invited to have their final MRI scan at the time of withdrawal 
to minimize missing MRI data. 
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cartilage. G, A hyperlntenslty in the subchondral bone at the medial femoral 
compartment. H. The manual drawing process of the hyperlntense area. Bone 
marrow lesions on adjacent slices were measured and compared to locate the 
slice with the maximum lesion size. This was done for the medial femoral. 
medial tibial, lateral femoral. lateral tibial. and patellar compartments. The total 
size of the bone marrow lesion was calculated as the sum of every lesion within 
each compartment. 
Cartilage Volume 
Knee tibial cartilage volume was assessed on the sagittal 
Tl-weighted sequences using OsiriX software (University of 
Geneva) and femoral cartilage volume was assessed using the 
Cartiscope (ArthroLab Inc). 20 The volumes of the tibial carti-
lage plates (medial tibia and lateral tibia) were isolated from 
the total volume by manually drawing disarticulation con-
tours around the cartilage boundaries on a section-by-section 
basis. These data were then resampled using bilinear and 
cubic interpolation for the final 3-dimensional images 
(Figure 1). The coefficient of variation was 2.1% to 2.2% for 
intraobserver and interscan repeatability.21 
Femoral cartilage volume was measured directly from a 
standardized view of3-dimensional cartilage geometry as 
the sum of elementary volumes for the medial and lateral 
condyles delineated by the Blumensaat line.20 The segmen-
tation of the cartilage-synovial interfaces was carried out 
with a semiautomatic method under reader supervision and 
with corrections when needed (Figure 1). The coefficient of 
variation was 1.6% to 2.6% for intraobserver and interscan 
repeatability. 22 
Tibiofemoral cartilage volume was defined as the sum of 
both the tibial and femoral compartment cartilage volume 
and was calculated at screening and at 24 months. Absolute 
change in tibiofemoral cartilage volume was calculated as 
tibiofemoral cartilage volume at 24 months minus tibio-
femoral cartilage volume at baseline. The percentage change 
in tibiofemoral cartilage volume per year was calculated as 
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follows: 100 × [(follow-up cartilage volume − baseline carti-
lage volume)/baseline cartilage volume]/exact time between
2 scans in years.
Bone Marrow Lesions
The ill-defined hyperintensities in the subchondral bone vi-
sualized on MRI were considered to be bone marrow lesions.
The bone marrow lesions were assessed on the sagittal pro-
ton density–weighted sequences at the medial tibial, medial
femoral, lateral tibial, lateral femoral, and patella sites using
OsiriX software. The maximum size of each lesion was mea-
sured by applying software cursors to the greatest area of the
lesion as previously described.12 Total bone marrow lesion size
was calculated as the sum of every lesion within each site at
screening and at 6 and 24 months (Figure 1). The intraclass cor-
relation coefficients (2-way mixed-effects model) of bone mar-
row lesion size ranged from 0.84 to 0.91.
Assessment of Pain
Knee pain was assessed by a 100-mm VAS (a score of 0
[none] to 100 [unbearable]) and the 500-mm WOMAC pain
scale (a score of 0 [none] to 500 [unbearable]) over the past
7 days. Five items were assessed, including pain during
walking on a flat surface, going up and down stairs, at night
while in bed, sitting or lying, and standing upright, and were
summed to create a total WOMAC pain score.23 The WOMAC
pain score was considered invalid if there was more than 1
missing item.
Adverse Events
Adverse events were monitored throughout the trial. All par-
ticipants were requested to report any adverse event to the re-
search staff at each study visit and by telephone between vis-
its. Moreover, participants were telephoned 3 days following
their infusions at baseline and at 12 months to determine if they
experienced any of the following types of adverse effects af-
ter the infusion: fever, musculoskeletal, gastrointestinal, or eye
symptoms and any other adverse effects as previously
described.24 The presence of serious adverse events (ie, death,
life-threatening, disabling, nonelective or prolonged hospi-
talization, and important medical events such as cancer) was
determined by a rheumatologist.
Power Calculations
For change in tibiofemoral cartilage volume, the sample size
was calculated based on the assumption that a decrease in
bone marrow lesion size would result in a reduction in carti-
lage volume loss over time. This assumption was based on
evidence from observational data demonstrating that bone
marrow lesions were associated with cartilage volume loss
over time.25-28 Data from the pilot study showed that zoled-
ronic acid decreased bone marrow lesion size compared with
placebo (−199 mm2 vs −23 mm2) over 6 months.12 These data
and unpublished observational data from the Tasmanian
Older Adult Cohort study were used to estimate the associa-
tion of a decrease in bone marrow lesion size with change
in tibiofemoral cartilage volume over 24 months. Estimates
of tibiofemoral cartilage loss expected from the magnitude of
changes observed in bone marrow lesion size were −824 mm3
(SD, 273 mm3) in the zoledronic acid group and −928 mm3
(SD, 272 mm3) in the placebo group (the minimal clinically
important difference was not defined for cartilage volume
loss). With this difference (104 mm3), 132 participants in
each group would provide 80% power with 5% probability of
type I error (α = .05), allowing for a dropout rate of 20% over
24 months. The power to detect a clinically important differ-
ence was 99.3% for a VAS knee pain score of 15 (range, 0-100)
and 97.3% for a bone marrow lesion size of 140 mm2.
Statistical Analysis
The statistical analysis plan is provided with the study proto-
col (eAppendix in Supplement 1). The primary analyses were
performed based on the original randomization group for
each participant. Change in tibiofemoral cartilage volume,
knee pain, and bone marrow lesion size were analyzed using
linear mixed-effects models with treatment, month, and the
treatment × month interaction as covariates. The correlations
within trial site and the repeated measures were addressed
using trial site and participant identification as random inter-
cepts. Month was treated as a random effect, and an unstruc-
tured covariance structure was used to allow different treat-
ment effects over time. Each model was adjusted for the
baseline value of the corresponding outcome (eg, change in
cartilage volume was adjusted for baseline cartilage volume).
Missing data caused by loss to follow-up and nonresponses
were addressed by adding baseline complete variables that
explained the missingness to the regression models.
Prespecified subgroup analyses were performed to exam-
ine which subgroups may respond better to treatment. One pre-
specified stratification variable was presence or absence of ra-
diographic JSN (grade 1 or 2 vs grade 0). This was conducted
by introducing a 3-way interaction between treatment, month,
and radiographic JSN in the linear mixed-effects models. Other
prespecified subgroup analyses using MRI readings for patho-
logical effects (ie, cartilage defects and meniscal tears and ex-
trusion) were not conducted because these MRI readings have
not been completed.
In the secondary analyses,14 per-protocol analyses were
conducted for the primary and secondary outcomes by the
actual treatment that the participants received, and this was
limited to those who received infusions at both baseline and
12 months. Multiple imputation with chained equations was
used to address missing data, with 20 imputations performed
by treatment group using baseline complete variables (age,
sex, body mass index, and study site) and nonmissing values
of the outcomes at baseline and at each follow-up, and
assuming the data were missing at random.
A post hoc subgroup analysis was performed by baseline
bone marrow lesion size (larger [>median size] or smaller
[<median size]). Post hoc conditional power analyses were
performed based on both the designed detectable effects and
the clinically important effects on study end points using the
observed SDs in this trial. Some participants had missing
measurements for tibial, femoral, or both tibial and femoral
cartilage volume; therefore, a comparison was conducted to
evaluate the effect of zoledronic acid on cartilage volume loss
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in participants with complete data on tibiofemoral cartilage
volume vs those with measures of cartilage volume only at
either the tibial or the femoral site.
Because of the potential for type I error due to multiple
comparisons, the findings for the analyses of the secondary
outcomes and for the subgroup analyses should be inter-
preted as exploratory. All analyses were performed with Stata




The study flowchart appears in Figure 2. From November
2013 through September 2015, 408 participants were
screened and 223 were randomized to receive zoledronic
acid (n = 113) or placebo (n = 110). The final date of follow-up
was October 9, 2017. The planned sample size (n = 264) was
not achieved due to budgetary limitations. One participant
in the placebo group incorrectly received zoledronic acid
infusions at both baseline and 12 months. Thirty-three par-
ticipants (15%) withdrew from the trial (23 [20%] in the
zoledronic acid group and 10 [9%] in the placebo group), and
190 participants (85%) completed the study. The baseline
characteristics of all participants (both those who completed
the study and those who did not) appear in eTable 1 in
Supplement 2.
The mean age of the participants was 62.0 years (SD, 8.0
years), and 117 (52%) were women. The baseline characteris-
tics of the 2 study groups were generally well balanced. How-
ever, the mean value of knee pain scores was higher and the
cartilage volume was lower in the placebo group than in the
zoledronic acid group (Table 1).
Figure 2. Population Eligibility and Inclusion in the Zoledronic Acid for Osteoarthritis Knee Pain (ZAP2) Study
408 Participants screened
185 Excluded
45 Severe radiographic osteoarthritis
23 Poor dental fitness
13 Abnormal blood test results
9 Ineligible pain score
4 Prior use of bisphosphonates
4 Had other form of arthritis
3 Contraindication to magnetic resonance imaging
2 Did not meet American College of Rheumatology criteria
1 Planned knee surgery
1 Prior diagnosis of cancer
1 Underwent arthroscopy within past year
1 Prior use of an investigational drug
39 No bone marrow lesion
39 Withdrew before intervention
223 Randomized
113 Randomized to receive zoledronic acid 110 Randomized to receive placebo
114 Received first infusion of zoledronic
acid at baselinea
109 Received first infusion of placebo
at baselinea
113 Included in primary analysisd
88 Included in per-protocol analysisd
110 Included in primary analysisd
99 Included in per-protocol analysisd
18 Discontinued study
0 Lost to follow-up
7 Underwent knee surgery
4 Physically unwellb
4 Withdrawal by participant
2 Worried about acute reactions
1 Relocated
5 Discontinued study
1 Underwent knee surgery
2 Physically unwellb
2 Withdrawal by participant
2 Lost to follow-up
88 Received second infusion of
zoledronic acid at 12 moa
8 Discontinued treatmentc
99 Received second infusion of
placebo at 12 moa
3 Discontinued treatmentc
4 Discontinued study
1 Lost to follow-up
2 Withdrawal by participant
1 Underwent knee surgery
1 Relocated
2 Discontinued study
1 Lost to follow-up
1 Underwent knee surgery
1 Unknown
a One participant allocated to the
placebo group incorrectly received
zoledronic acid at both baseline and
12 months.
b Participants who had major surgery
(eg, heart surgery, hip replacement,
back surgery) or wished to have an
antiresorptive treatment
(denosumab).
c Participants who did not receive the
second infusion but continued with
the study visits and assessments.
d For change in cartilage volume, 194
participants with data on both tibial
and femoral cartilage volume at
baseline were included in the
primary analysis (93 in the
zoledronic acid group and 101 in the
placebo group) and 163 were
included in the per-protocol analysis
(79 and 84, respectively).
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Primary Outcome 
Tibiofemoral cartilage volume decreased by a mean value of 
878 mm3 in the zoledronic acid group and 919 mm3 in the pla-
cebo group over 24 months and the between-group differ-
ence was not statistically significant (between-group differ-
ence, 41 mm3 [95% CI, -79 to 161 mm3J, P = .50; Table 2). 
Secondary Outcomes 
Knee pain improved in both groups over 24 months and there 
was no significant between-group difference observed for the 
VAS pain score (-11.5 for the zoledronic acid group vs -16.8 for 
the placebo group; between-group difference, 5.2 [95% CI, -2.3 
to 12.8]; P = .17) orforthe WOMAC pain score (-37.5 vs -58.0, 
respectively; between-group difference, 20.5 [95% CI, -11.2 to 
52. 21; P = . 21) or at any other time point (Table 2 and Figure 3). 
Bone marrow lesion size was not significantly changed in either 
group and no significant between-group differences were ob-
served over 24 months ( -33 mm2 for the zoledronic acid group 
vs -6 mm2 for the placebo group; between-group difference, 
-27mm2 [95%CI, -127to73 mm2J;P = .60) orover6 months 
(Table 2 and Figure 3). 
The results of the prespecified subgroup analyses appear 
in eFigure 1 in Supplement 2. The effect of zoledronic acid on 
the change in tibiofemoral cartilage volume was not signifi-
cantly different in participants with or without radiographic 
JSN. A significant interaction between treatment and radio-
graphic JSN for change in WOMAC knee pain score was ob-
served after 12 months (P = .01 for interaction). Zoledronic acid 
significantly improved WOMAC knee pain score among par-
ticipants without radiographic JSN (n = 44) over 12 months 
compared with placebo (between-group difference, -67.9 [95% 
CI, -126.8 to -8.9], P = .01). There were statistically signifi-
cantinteractions between treatment and radiographic JSN for 
both the WOMAC and VAS knee pain scores after 24 months, 
but compared with placebo, zoledronic acid did not signifi-
cantly improvethe WOMAC orVASknee painscoreamongpar-
ticipants with or without radiographic JSN. 
In prespecified secondary analyses, neither the per-
protocol analyses nor multiple imputation changed the re-
sults meaningfully from the primary analyses (eTables 2 and 
3 in Supplement 2). 
Post Hoc Analyses 
Even though significant interactions between treatment and 
bone marrow lesion size (>the median size vs <the median 
size) were found for WOMAC knee pain score after 12 and 18 
months and for VAS knee pain score after 6 months, zoled-
ronic acid did not significantly improve knee pain in partici-
pants with larger or smaller bone marrow lesions compared 
with placebo (eFigure 2 in Supplement 2). In the post hoc 
conditional power analyses, this trial had sufficient power to 
detect a clinically important difference in cartilage loss 
(power= 1.0; eTable 4 in Supplement 2). The effect ofzoled-
ronic acid on cartilage loss in participants with data on tibial 
or femoral cartilage volume (n = 188) or with complete data 
on both tibial and femoral cartilage volume (n = 142) was not 
meaningfully different from the primary analysis (n = 194; 
eTable 5 in Supplement 2). 
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Table 1. Patient Demographics and Baseline Characteristics 
Zoledronlc acid Placebo 
(n = 113) (n = 110) 
Age, mean (SO}, y 62.6 (8.5) 61.3(7.3) 
Sex, No.(%} 
Female 54 {48) 63 (57) 
Male 59 (52) 47 {43) 
Body mass Index, mean (SD)" 30.2 (5.5) 30.8 (6.2) 
Radiographic JSN, No./total (%)" 
Grade O (normal) 21/110 (19) 23/108 (21) 
Grade 1 (mild) 39/110 (36) 48/108 {45) 
Grade 2 (moderate) 50/110 {45) 37 /108 {34) 
Tlblofemoral cartilage volume, (n = 101) (n = 93) 
mean (SD), mm3 16 994 (7273) 16 039 (6807) 
Tibial cartilage volume, 
mean (SD), mm 3 
3371 (1213) 3247 (1044) 
Femoral cartila~e volume, 
mean (SD), mm 
(n = 101) 
13 529 (6497) 
(n = 93) 
12 787 (6128) 
Bone marrow lesion size, 
median {IQR), mm 2 
476 (255-860) 502 (225-919) 
Knee pain score, mean (SD) 
WOMAC' 180.8 (103.7) (n = 109) 
219.9 (103.0) 
Visual analog sea 1e• 47.7 (21.2) (n = 108) 
54.5 (19.2) 
Concomitant medications 
No. of analges Jes, 1 (0-2) 1 (0-2) 
median {IQR) 
NSAIDs, No.(%) 52 {46) 59 {54) 
Paracetamol/aceta m lnophen, 58 (51) 46 {42} 
No.{%} 
Other ana lgesics, No.(%)• 8 (7) 11 (10) 
Glucosamine or chondroitin, No.(%) 31 (27) 33 (30) 
Abbrev1ations: IQR, interquartile range, JSN, joint space narroWing, 
NSAIDs. nonsteroidal anti-inflammatory drugs, WOMAC, Western Ontario and 
McMaster Universities Osteoarthritis Index. 
• Calculated as weight In kilograms divided by height In meters squared. A body 
mass index of 18.5 to 25 was considered a healthy weight: 26 to 30, 
overweight, and greater than 30, obese. 
0 Assessed according to the atlas from the Osteoarthritis Research Society 
International (a score of o Indicates normal: 1, mild: 2, moderate, and 3, 
severe). 
' Range is o to 500: higher scores indicate more severe symptoms. The index 
relies on a self-administered questionnaire reflecting pain, stiffness, and 
limitations to physical function. The pain subscale measures 5 dimensions: 
walking on a flat surface, going up and down stairs. at night while in bed, 
sitting or lying. and standing upright. 
• Range Is o to 100: higher scores Indicate more severe symptoms. 
• Jnduded opiolds. prednisolone, and compound analgesics. 
Adverse Events 
The adverse event rates appear in Table 3. One hundred and 
eight participants (96%) in the zoledronic acid group and 91 
participants (83%) in the placebo group experienced at least 1 
adverse event. The between-group difference was primarily 
due to the higher rate of acute reactions with zoledronic acid 
than with placebo (87% vs 56%, respectively). Acute reac-
tions within 3 days of the infusion consisted primarily of mus-
culoskeletal pain and stiffness (70% in the zoledronic acid 
group vs 30% in the placebo group), fever (52% vs 8%, respec-
tively), and headache and dizziness (42% vs 26%). These 
JAMA April 21. 2020 Volume 323, Number 15 1461 
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symptoms were less prevalent in both groups after the sec-
ond infusion. Two participants (2%) in the zoledronic acid
group withdrew due to acute reactions.
Adverse events other than acute reactions were similar in
the zoledronic acid and placebo groups (68% vs 67%, respec-
tively) throughout the trial, except that more knee replace-
ment procedures were performed in the zoledronic acid group
compared with the placebo group (9% vs 2%). The incidence
of serious adverse events was similar in the zoledronic acid
group (20%) and in the placebo group (22%).
Discussion
During a 2-year period, 2 annual infusions with 5 mg of zole-
dronic acid compared with placebo did not significantly
decrease cartilage volume loss, knee pain, or bone marrow
lesion size in participants with symptomatic knee osteoar-
thritis and subchondral bone marrow lesions. These findings
do not support the use of zoledronic acid for slowing carti-
lage volume loss or alleviating knee pain in patients with
knee osteoarthritis.
This trial adds in several ways to 2 prior clinical trials
(n = 2483 and n = 284) that showed no effect of bisphospho-
nates on progression of knee osteoarthritis.29,30 First, this
study was designed for patients with a subchondral bone
marrow lesion who may be more likely to benefit from bis-
phosphonate therapy.31 Second, the exclusion of patients
with severe radiographic JSN minimized a floor effect,32
given that patients with severe radiographic JSN have only a
small volume of cartilage remaining. Third, in contrast to
prior trials, the current trial directly measured cartilage vol-
ume using MRI, which is more sensitive to change compared
with a surrogate measure of cartilage volume (ie, radio-
graphic JSN).33 Fourth, the current trial followed up partici-
pants for 2 years. In contrast, the 1-year follow-up in 1 of the
prior trials29 may have been too short to observe change in
radiographic JSN (as a measure of disease progression). Fifth,
the most potent intravenous bisphosphonate (ie, zoledronic
acid) was used. Sixth, the annual administration of zoled-
ronic acid increased patients’ adherence to treatment.34
This trial was designed to detect a between-group differ-
ence of 104 mm3 in cartilage volume loss over 2 years based
on pilot RCT data12 and a surrogate marker (bone marrow le-
sion) of cartilage loss. Neither of these outcomes has a de-
fined minimal clinically important difference. It is important
to know whether the threshold effect that the study was de-
signed to detect (104 mm3) is clinically important. Cartilage
loss has been associated with an increased risk of knee re-
placement, and every 1% per-year increase in cartilage loss is
associated with a 20% increase in the risk of knee replace-
ment surgery over 4 years.35 Based on this, the amount of car-
tilage loss equivalent to 1% per year in this clinical trial popu-
lation was calculated to be 331 mm3 over 2 years (mean cartilage
volume at baseline = 16 536 mm3 and 331 = 16 536 mm3 × 1% × 2
years). Therefore, this trial was designed to detect a small ef-
fect (104 mm3), and one that was much smaller than the esti-
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Figure 3. Effect of Zoledronic Acid on Knee Pain and Bone Marrow Lesion Size Compared With Placebo 
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Table 3. Adverse Events 
No.(%) 
Zoledronlc acid Placebo 
(n = 113) (n = 110) 
Adverse events 
Any 108 (96) 91 (83) 
Any serious• 23 (20) 24 (22) 
Any acute reactions• 98 (87) 61 (56) 
Acute reaction after first Infusion 97 (86) 50 (46) 
Acute reaction after second infusion 41 (36) 28 (26) 
Acute reaction categories 
Eye inflammation and pa In 11 (10) 6 (6) 
Fever 59 (52) 9 (8) 
Gastrointestinal symptoms 30 (27) 13 (12) 
Musculoskeletal pain and stiffness 79 (70) 33 (30) 
Other 82 (73) 44 (40) 
Fatigue 44 (39) 16 (15) 
Headache and dizziness 47 (42) 29 (26) 
I nfluenzalike illness 21 (19) 3 (3) 
Malaise and insomnia 33 (29) 11 (10) 
Pain 24 (21) 7 (6) 
Unclassified 23 (20) 12 (11) 
Nonacute reaction categories 77 (68) 74 (67) 
Cancer 3 (3) 3 (3) 
Ca rdlovascula r diseases 7 (6) 9 (8) 
Oisk degeneration 2 (2) 2 (2) 
Elective hosp ital ad m isslons' 35 (31) 44 (40) 
Gastrointestinal symptoms 2 (2) 6 (5) 
Hernia 1 (1) 1 (1) 
Injuries• 12 (11) 8 (7) 
Knee replacement 10 (9) 2 (2) 
Malaise and insomn la 1 (1) 4 (4) 
Musculoskeletal pain and stiffness 39 (35) 35 (32) 
Neuropathy 1 (1) 4 (4) 
Other problems• 0 5 (5) 
Pneumonia 1 (1) 2 (2) 
Skin diseases 1 (1) 1 (1) 
• Defined as death, life-threatening, disabling, nonelectfve or prolonged 
hospitalization. or important medical events such as cancer. 
• Typically occur and resolve within 3 days of zoledronlc acid infusion, these 
include fever, musculoskeletal. gastrointestinal, eye, or other symptoms. 
' Mostly diagnostic examinations (eg, bronchoscopy, cystoscopy, colonoscopy, 
and gastroscopy), planned surgery for Injuries, or long-term conditions 
unrelated to the knee or musculoskeletal system. 
• Mostly due to falls and accidents. Five injuries were related to the knee 
(1 in the zoledronic acid group and 4 in the placebo group). 
• Single adverse events Included enlarged prostate, gluten sensitivity, sore 
throat. whooping cough, and type 2 diabetes. 
This trial may have included an unnecessarily large 
sample size for the outcome of cartilage volume, increasing 
the precision for estimating treatment effects. Post hoc con-
ditional power analyses also suggested that this trial had suf-
ficient statistical power to detect the estimated clinically 
important effect on cartilage loss (331 mm3; eTable 4 in 
Supplement 2). The observed 95% CI for cartilage loss (-79 
to 161 mm3) did not include the estimated clinically impor-
1464 JAMA April 21, 2020 Volume 323, Number 15 
tant effect (331 mm3), indicating the effect of zoledronic acid 
on cartilage loss was small and did not meet the criterion for 
a clinically important effect. For the secondary outcomes, 
the observed 95% Cis did not include clinically important 
differences for either pain or bone marrow lesion size. Based 
on these results, it is unlikely that a clinically important 
effect was missed. A larger study is unlikely to yield a differ-
ent result. 
In a previously completed pilot study of patients with knee 
osteoarthritis, zoledronic acid significantly reduced both knee 
pain score (-14.5 [95% CI, -28.1 to -0.9]) and bone marrow le-
sion size (-176 mm2 [95% CI, -327to -24 mm2]) compared with 
placebo over 6 months, 12 but these preliminary findings were 
not replicated in this larger multicenter trial using the same 
protocol. In this trial, the between-group difference in knee 
pain score over 6-month follow-up was 1.0 (95% CI, -5.0 to 7.0) 
and in bone marrow lesion size was -13 mm2 (95% CI, -67 to 
42 mm2). The comparison of the 95% Cissuggests that the sta-
tistically significant results in the pilot study were likely due 
to chance. 
Subgroup analyses showed an interaction of JSN for the 
effects of zoledronic acid treatment on knee pain, in which pa-
tients without radiographic JSN had greater improvement in 
WOMAC knee pain score vs those with radiographic JSN. How-
ever, compared with placebo, zoledronic acid did not signifi-
cantly improve knee pain score using the WOMAC or the VAS 
in participants with or without JSN. There was a significant im-
provement for WOMAC knee pain score over 12 months among 
those without JSN in the zoledronic acid group. These results 
are consistent with previous findings that zoledronic acid im-
proved back pain in patients with mild but not severe disc 
degeneration. 36 A possible explanation is that bone resorp-
tion increases in early-stage osteoarthritis but decreases as the 
disease progresses. 37 Antiresorptive agents may help to im-
prove knee pain in those without radiographic JSN (early-
stage osteoarthritis) but not in those with radiographic JSN 
(later-stage osteoarthritis). These observations should be 
viewed as exploratory. 
Ad verse events in this trial were common and there was a 
higher frequency ofacute reactions (eg, musculoskeletal pain, 
fever, and headache and dizziness) within 3 days of treat-
ment in patients who received zoledronic acid compared with 
placebo. This is consistent with a prior report. 24 More knee re-
placements occurred in the zoledronic acid group (9%) com-
pared with the placebo group (2%) over 24 months. This find-
ing differs from 2 observational studies38,39 that suggested a 
lower risk of knee replacement in patients with bisphospho-
nate use compared with those without bisphosphonate use. 
The reasons for this discrepancy are unclear. 
Limitations 
This study has several limitations. First, the planned sample 
size was not reached. However, as discussed above, it is un-
likely that a clinically important effect was missed for any of 
the primary and secondary outcomes. 
Second, 1 patient assigned to the placebo group incor-
rectly received zoledronic acid treatment at both baseline and 
12 months. However, the per-protocol analyses produced 
Jama.com 
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similar results compared with the primary analyses, suggest-
ing no effect from misallocation.
Third, baseline WOMAC pain score was substantially dif-
ferent between the groups, but this was adjusted for in the re-
gression models evaluating the treatment effect on knee pain.
Fourth, there was a differential rate of follow-up. The loss
to follow-up rate was 20% in the zoledronic acid group com-
pared with 9% in the placebo group. This differential follow-up
rate has the potential to influence the missing at random as-
sumption used for addressing missing data. The difference in
loss to follow-up rates per group was mainly due to the higher
incidence of knee replacement surgery in the zoledronic acid
group (9% vs 2% in the placebo group).
Conclusions
Among patients with symptomatic knee osteoarthritis and bone
marrow lesions, yearly zoledronic acid infusions, compared
with placebo, did not significantly reduce cartilage volume loss
over 24 months. These findings do not support the use of zole-
dronic acid in the treatment of knee osteoarthritis.
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